Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 0-2 months (must be gestational age 37 to 41 weeks)~* Scheduled to undergo routine contrast-enhanced liver MRI~* Able to comly with the study procedures~Exclusion Criteria:~* Scheduled for any intervention (except lumbar puncture and bone marrow aspiration) during the study period~* If receiving chemotherapy, may have a change in treatment during the study period~* Contraindication for MRI~* Renal insufficiency (estimated glomerular filtration rate \< 80% of age-adjusted normal mean value using the Schwartz formula)~* Acute renal failure~* Clinically relevant abnormal laboratory parameter, ie, greater than 3 times the upper limit of the normal range, in particular, liver enzymes and renal function. (Note: if elevations in liver enzyme levels are consistent with the underlying hepatobiliary disease, then the subject may be enrolled.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Months
- Healthy Volunteers: f

Study Arms:
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873) (Type: EXPERIMENTAL): Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.

Based on this trial design, predict the completion outcome and termination type (if applicable).